Peter Hillmen
Leeds Teaching Hospitals NHS Trust · 620 works · 47,797 citations · h-index 92
Top works
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
- The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
- Natural History of Paroxysmal Nocturnal Hemoglobinuria
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria
- Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
- Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG‐A gene.
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
- Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia